“Arthramid® Vet is used by veterinarins everyday and around the world for the treatment of lameness in horses. Multiple published studies from high profile institutions, and treating thousands of equine patients across all equestrian disciplines, show that Arthramid®Vet is a safe and effective treatment for osteoarthritis and joint lameness in animals. Explore this page for more information and to access findings from studies of Arthramid® Vet 2.5% PAAG”
Innovative Medical Solutions
Arthramid Vet White Paper
Veterinarians: Get your copy of our 24 page white paper today, covering Treatment of Joint Lameness, Pathophysiology, Manufacturing, Mechanism of Action, Clinical Safety and Putting it into Practice.
Janssen, I., Koene, M., and Lischer, C. (2012). Intraarticular application of polyacrylamide hydrogel as a treatment of osteoarthritis in the distal interphalangeal joint: Case series with 12 horses
Tnibar et al (2014). Evaluation of a polyacrylamide hydrogel in the treatment of induced osteoarthritis in a goat model: a randomized controlled pilot study
Tnibar et al (2015). An international multi-centre prospective study on the efficacy of an intraarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 months follow-up
Christensen, L., Illigen, K.E., Hansen, M., Sarvaa, R., and Conogham, P.G. (2016). Synovial incorporation of polyacrylamide hydrogel after injection into normal and osteoarthritic animal joints
Bathe, A.P., Read, R.M., and Briggs, C. (2016). Intra-articular polyacrylamide hydrogel for the treatment of 20 horses with non-responsive osteoarthritis of the interphalangeal joints: a prospective study
Tnibar,A., Persson, A.B., and Jensen, H.E. (2017). Mechanisms of Action of an Intraarticular 2.5% Polyacrylamide Hydrogel (Arthramid Vet) in a Goat Model of Osteoarthritis: Preliminary Observations
Henrikson, M., Overgaard, A., and Bliddal, H. (2017). Initial Estimates of Efficacy of Intra-Articular 2.5% Polyacrylamide Hydrogel for the Treatment of Knee Osteoarthritis: An Observational Proof-of-Concept Study
de Clifford, L.D., Lowe, J.N., McKellar, C.D., Bolwell, C., and David, F. (2019). Use of a 2.5% Cross-Linked Polyacrylamide Hydrogel in the Management of Joint Lameness in a Population of Flat Racing Thoroughbreds: A Pilot Study
Treatment of Joint Lameness and Osteoarthritis (OA)
Osteoarthritis (OA) is considered one of the most important musculoskeletal disorders in both humans and horses. 1, 2 Clinically, it is associated with lameness and dysfunction of the affected joint and approximately 60% of all equine lameness is due to OA. 3, 4It is characterised by breakdown and loss of joint cartilage, bony overgrowths (osteophytosis- seen on radiographs),
- Novel treatment for lameness.
- Treats underlying disease process.
- Positive effect on articular components.
- Reduces mechanoreceptor activation.
- Long lasting tissue compatibility.
Clinical Safety of Arthramid Vet 2.5% PAAG Hydrogel
Both in vitro and in vivo studies have taken place, designed to generate data on the safety of Arthramid Vet and to support regulatory submissions for market authorisation. Most current OA treatments are focused on reducing symptoms, and there are few effective treatments that address the underlying cause of the disease.
- Multiple Safety Studies.
- No adverse side effects.
- Widespread use in human medicine.
- Safe for competiton.
ARTHRAMID VET 2.5% PAAG – MECHANISM OF ACTION
Arthritis describes inflammation of a joint and can happen after either a single or repetitive episodes of trauma. 31 The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and osteoarthritis or OA. These pathological conditions are ‘a group of overlapping distinct diseases which may have different causes, but with similar biologic, anatomical, and clinical outcomes.’
- Integrates into joint capsule.
- Restoring function to the joint.
- Increasing visco-elastic.
- Reduces pain & synovitis.
- Stable & non-absorbable.
PIVOTAL EFFICACY STUDY – RANDOMISED, ODUBLE BLIND POSITIVE CONTROL STUDY
Introduction: Intra-articular administration of a 2.5% polyacrylamide hydrogel (PAAG- Arthramid Vet) is shown to reduce or abolish lameness in distal interphalangeal (coffin) and metacarpo/ metatarso- phalangeal (fetlock) joints in horses undertaking equestrian disciplines. To date, there had been no studies evaluating the effect in racehorses of Arthramid Vet (2.5% PAAG) against positive control treatments.
Objectives: To investigate the efficacy of a 2.5% PAAG (Arthramid Vet) in the management of inter-carpal joint lameness in racing Thoroughbreds against the traditional treatments of HA and TA.
Study design: Prospective double-blinded positive-control study.
Testimonials From Clinical Practice
32 Hill Road, Cambridge, NZ Phone +64 (09) 8013 253 firstname.lastname@example.org
Interested in talking to us and learning more?
Arthramid Vet New Zealand
Registered in New Zealand to: Innovative Medical Solutions Limited NZBN: 9429041325544, 32 Hill Road, Cambridge 3494, New Zealand. Registered pursuant to the ACVM Act 1997 Number A11596. See www.foodsafety.govt.nz for registration conditions.
For use only by a veterinarian. Ask your vet to contact us today.